Physician profile
David Linz
NPI 1821198342
$903.93
in general payments reported to CMS, 2019-2025
14 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $121 · 2022: $83.33 · 2023: $80.98 · 2024: $72.52 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $190.10 | 2019-2023 | Echelon Circular, Harmonic, Echelon Flex |
| Merit Medical Systems INC | $135.21 | 2019 | |
| Haemonetics Corporation | $124.04 | 2025 | Teg6s Hemostasis System |
| Zimmer Biomet Holdings, INC. | $105.46 | 2020 | |
| Covidien LP | $86.59 | 2019 | |
| Abbvie INC. | $62.90 | 2019-2020 | |
| Tela Bio, INC. | $46.69 | 2024 | Ovitex 2s |
| Baxter Healthcare | $26.98 | 2019 | |
| Celgene Corporation | $25.83 | 2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $25.30 | 2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $22.60 | 2023 | Dificid |
| Medtronic, INC. | $21.04 | 2025 | V-Loc 180 |
| Astrazeneca Pharmaceuticals LP | $15.79 | 2019 | |
| Seagen INC. | $15.40 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Linz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.